To test if DOT1Ls enzymatic activity is relevant for its function in blast-phase MPN and whether co-treatment with DOT1L- and LSD1 inhibitors could be a viable therapeutic approach, we evaluated this combination in vitro. The gene discussed is KDM1A; the disease is myeloproliferative disorder.